Cetuximab and panitumumab for treating RAS wild-type colorectal cancer

Published on 01 Apr 2022
Last Updated on 01 Apr 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Brinzolamide 1% eye drops; and

• Brinzolamide/timolol 1%/0.5% eye drops

in line with their registered indications for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in view of acceptable price proposals from the manufacturer.

Subsidy status

Brinzolamide 1% and brinzolamide/timolol 1%/0.5% eye drops are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy does not apply to brinzolamide/brimonidine 1%/0/0.2% eye drops in view of unacceptable price proposal from the manufacturer.

Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension (1 Apr 2022) [PDF, 123 KB]